Is Alpha Teknova, Inc. technically bullish or bearish?
2025-09-20 19:45:42As of 25 August 2025, the technical trend for Alpha Teknova, Inc. has changed from mildly bearish to bearish. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands and KST are both mildly bearish on both weekly and monthly time frames. The moving averages are also mildly bearish on a daily basis, while the Dow Theory shows a mildly bullish stance weekly but bearish monthly. In terms of performance, Alpha Teknova has underperformed the S&P 500 significantly year-to-date, with a return of -44.43% compared to the S&P's 12.22%, and over the past year, it has returned -7.39% versus the S&P's 17.14%. Overall, the current technical stance is bearish, indicating weakness in the stock's performance....
Read MoreIs Alpha Teknova, Inc. overvalued or undervalued?
2025-09-20 18:20:47As of 11 August 2021, the valuation grade for Alpha Teknova, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 4.03 and an EV to Sales ratio of 7.99, both of which suggest a premium valuation relative to its financial performance. Additionally, the negative EV to EBITDA of -18.40 further underscores the challenges the company faces in generating earnings. In comparison to peers, CytomX Therapeutics, Inc. is categorized as very attractive with a P/E ratio of 7.49, while both Capricor Therapeutics, Inc. and Ocuphire Pharma, Inc. are also deemed risky with P/E ratios of -4.15 and -2.46, respectively. This peer comparison highlights that Alpha Teknova is not only struggling with profitability but is also lagging behind its competitors in terms of valua...
Read More





